Creating a biobank for studying bilio-pancreatic diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a biobank that collects biological materials and clinical data to investigate the genetic predisposition to bilio-pancreatic diseases. It will utilize both prospective and retrospective approaches to evaluate the interplay between genetic and environmental factors in the development of these diseases. Samples will include blood, saliva, urine, stool, and other biological materials to facilitate comprehensive research into risk factors for disease prevention and early diagnosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age \>= 18 years
* signed informed consent

Exclusion Criteria:

* age \< 18 years
* unwilling to sign informed consent

Where it's running

• IRCCS OSpedale San Raffaele
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Paolo Giorgio Arcidiacono, MD — IRCCS Ospedale San Raffaele
• Study coordinator: Gabriele Capurso, MD
• Email: capurso.gabriele@hsr.it
• Phone: 02/26436548

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Paracetamol with ibuprofen versus paracetamol with metamizole for pain in children with acute pancreatitis

  We will test whether IV paracetamol combined with ibuprofen or IV paracetamol combined with metamizole reduces pain more effectively in children aged 3–18 with acute pancreatitis.

  Recruiting Phase 4 Medical University of Warsaw · Warsaw · NCT07024199

• Collecting medical information and tissue samples from patients with pancreatic disorders

  This study is collecting medical information and samples from people with pancreatic cancer or other pancreatic disorders to help find better ways to detect and treat these diseases.

  Recruiting at 3 sites Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT00830557

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Short-stay aggressive hydration to prevent post-ERCP pancreatitis

  This trial tests whether a short, high-volume IV hydration with Lactated Ringer's plus a rectal indomethacin can prevent post-ERCP pancreatitis in adults undergoing ERCP.

  Recruiting Westmead Hospital · Westmead, New South Wales · NCT07776561

• Phosphate therapy for adults with acute pancreatitis

  This study tests whether giving phosphate through an IV can help adults with acute pancreatitis treated in the emergency department.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT07681050

• XYA02 in advanced solid tumors

  This trial tests XYA02 in adults with MUC1-expressing advanced or relapsed solid tumors to see if it is safe, tolerable, and can shrink tumors.

  Recruiting at 2 sites Phase 1/2 XYone Therapeutics, Inc · Sydney, New South Wales and 4 other locations · NCT07670312

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.